Recent Research Analysts’ Ratings Updates for Syros Pharmaceuticals (SYRS)

A number of firms have modified their ratings and price targets on shares of Syros Pharmaceuticals (NASDAQ: SYRS) recently:

  • 3/8/2019 – Syros Pharmaceuticals had its “mkt outperform” rating reaffirmed by analysts at JMP Securities. They now have a $18.00 price target on the stock.
  • 3/8/2019 – Syros Pharmaceuticals had its “hold” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock. They wrote, “Our price target of $10/share ($4.0 from tamibarotene + $3.4 from platform + $2.6 in cash) is based on a discounted cash flow analysis (2019-2027) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development-stage oncology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing.””
  • 3/8/2019 – Syros Pharmaceuticals was given a new $14.00 price target on by analysts at Roth Capital. They now have a “buy” rating on the stock.
  • 3/7/2019 – Syros Pharmaceuticals was given a new $13.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 2/14/2019 – Syros Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $13.00 price target on the stock.

Syros Pharmaceuticals stock traded up $0.49 during mid-day trading on Friday, reaching $8.88. 285,917 shares of the company were exchanged, compared to its average volume of 139,252. The firm has a market cap of $272.29 million, a P/E ratio of -4.65 and a beta of 1.22. Syros Pharmaceuticals Inc has a 12-month low of $5.17 and a 12-month high of $13.86.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Thursday, March 7th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.05). The company had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $0.40 million. Syros Pharmaceuticals had a negative return on equity of 64.43% and a negative net margin of 3,038.00%. Research analysts anticipate that Syros Pharmaceuticals Inc will post -2.1 earnings per share for the current year.

In other Syros Pharmaceuticals news, major shareholder Venture Fund Vii L.P. Arch sold 167,503 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $7.83, for a total transaction of $1,311,548.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 27.80% of the stock is owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC lifted its holdings in Syros Pharmaceuticals by 10.3% during the fourth quarter. Geode Capital Management LLC now owns 249,668 shares of the company’s stock worth $1,390,000 after buying an additional 23,234 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Syros Pharmaceuticals by 62.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 244,080 shares of the company’s stock worth $1,360,000 after buying an additional 93,728 shares during the period. D. E. Shaw & Co. Inc. lifted its holdings in Syros Pharmaceuticals by 763.7% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 88,882 shares of the company’s stock worth $496,000 after buying an additional 78,591 shares during the period. Bank of America Corp DE lifted its holdings in shares of Syros Pharmaceuticals by 205.9% during the 4th quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock valued at $98,000 after purchasing an additional 11,711 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Syros Pharmaceuticals by 3.3% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 122,561 shares of the company’s stock valued at $683,000 after purchasing an additional 3,900 shares during the last quarter. Institutional investors own 66.08% of the company’s stock.

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.

Featured Article: How are institutional investors different from individual investors?

Receive News & Ratings for Syros Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply